Health care workers and researchers traveling to developing-world clinical settings: Disease transmission risk and mitigation

Clinical Infectious Diseases

Volumn 51, Issue 11, 2010, Pages 1298-1305

  Kortepeter, Mark G ^a   Seaworth, Barbara J ^c   Tasker, Sybil A ^d   Burgess, Timothy H ^b   Coldren, Rodney L ^a   Aronson, Naomi E ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^d Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; TYPHOID VACCINE;

CHICKENPOX; DEVELOPED COUNTRY; DIPHTHERIA; DISEASE TRANSMISSION; HEALTH CARE PERSONNEL; HEMORRHAGIC FEVER; HEPATITIS A; HEPATITIS B; HUMAN; INFLUENZA A (H1N1); MEASLES; MEDICAL RESEARCH; MUMPS; NEEDLESTICK INJURY; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; REVIEW; RISK FACTOR; RUBELLA; TETANUS; TRAVEL; TUBERCULOSIS; TYPHOID FEVER; VIRAL RESPIRATORY TRACT INFECTION;

COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DEVELOPING COUNTRIES; HEALTH PERSONNEL; HUMANS; RESEARCH PERSONNEL; TRAVEL;

EID: 78649863793     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657115     Document Type: Review

References (57)

1. Trim JC, Elliott TSJ. A review of sharps injuries and preventative strategies. J Hosp Infect 2003; 53:237-242.
2. Tarantola A, Abiteboul D, Rachlinec A. Infection risks following accidental exposure to blood or body fluids in health care workers: a review of pathogens transmitted in published cases. Am J Infect Control 2006; 34:367-375. (Pubitemid 44108326)
3. Tarantola A, Rachlinec A, Konto C, et al. Occupational Plasmodium falciparum malaria following accidental blood exposure: a case, published reports and considerations for post-exposure prophylaxis. Scand J Infect Dis 2005; 37:131-140.
4. US Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001; 50(RR-11):1-52.
5. Habib S, Shaikh OS. Hepatitis B immune globulin. Drugs Today 2007; 43(6):379-394.
6. Corey KE, Mendex-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2009; 17(3):201-207.
7. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis 2004; 39:395-401.
8. World Health Organization. Joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection. 2007. http://www.who.int/hiv/pub/ prophylaxis/pep-guidelines/en/index.html. Accessed 24 April 2010.
9. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for post-exposure prophylaxis. MMWR Recomm Rep 2005; 54(RR-9):1-17.
10. Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill 2004; 9:E11-2.
11. Jahrling PB, Marty AM, Geisbert TW. Viral hemorrhagic fevers. In: Dembek ZF, ed. Medical aspects of biological warfare. Washington, DC: Department of the Army, Office of the Surgeon General, Borden Institute, 2007:271-310.
12. Peters CJ. Viral hemorrhagic fevers as agents of bioterrorism. In: Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. Philadephia, PA: Churchill, Livingstone, Elsevier, 2010:3995-3998.
13. Towner JS. Investigations of Marburg virus circulation among Egyptian fruit bats in southwest Uganda. Fifth International Symposium on Filoviruses, 18-21 April 2010, Tokyo, Japan. Abstract 7S-4.
14. Chen LH, Wilson ME. Transmission of dengue virus without a mosquito vector: nosocomial mucocutaneous transmission and other routes of dengue transmission. Clin Infect Dis 2004; 39:e56-e60.
15. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287(18):2391-2405.
16. Jaax N, Jahrling P, Geisbert T, et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995; 346:1669-1671.
17. Khan AS, Tshioko FK, Heymann DL, et al; Commission de Lutte contre les Epidémies à Kikwit. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(suppl 1):S76-S86.
18. Centers for Disease Control and Prevention. Outbreak of Ebola hemorrhagic fever - Uganda, August 2000 - January 2001. MMWR Morb Mortal Wkly Rep 2001; 50(5):73-77.
19. Centers for Disease Control and Prevention. Interim guidance for managing patients with suspected viral hemorrhagic fever in U.S. hospitals. http://www.cdc.gov/ncidod/dhqp/bp-vhf-interimGuidance.html. Accessed 7 February 2010.
20. Centers for Disease Control and Prevention. Update: management of patients with suspected viral hemorrhagic fever - United States. MMWR Morb Mortal Wkly Rep 1995; 44(25):475-479.
21. World Health Organization and Centers for Disease Control and Prevention. Infection control for viral hemorrhagic fevers in the African health care setting. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/vhfmanual.htm. Accessed 7 February 2010.
22. Centers for Disease Control and Prevention. Management of patients with suspected viral hemorrhagic fever. MMWR Morb Mortal Wkly Rep 1988; 37(suppl 3):1-16.
23. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and re-emerging infection. Clin Microbiol Rev 2007; 20(4):660-694. (Pubitemid 47623772)
24. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/disease/avian- influenza/country/cases-table-2010-04-09/en/index.html. Accessed 15 April 2010.
25. World Health Organization. Pandemic (H1N1) 2009 - update 95. http://www.who.int/csr/don/2010-04-09/en/index.html. Accessed 15 April 2010.
26. Reilley B, Van Herp M, Sermand D, Dentico N. SARs and Carlo Urbani. New Engl J Med 2003; 348:1951-1952.
27. Ofner-Agostini M, Gravel D, McDonald LC, et al. Cluster of cases of severe acute respiratory syndrome among Toronto healthcare workers after implementation of infection control precautions: a case series. Infect Control Hosp Epidemiol 2006; 27(5):473-478.
28. Chen WQ, Ling WH, Lu CY, et al. Which preventive measures might protect health care workers from SARS? BMC Public Health 2009; 9:81.
29. Yu IT, Li Y, Wong TW, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 2004; 350(17):1731-1739.
30. Wong TW, Lee CK, Tam W, et al. Cluster of SARS among medical students exposed to single patient, Hong Kong. Emerg Infect Dis 2004; 10(2):269-276.
31. Olsen SJ, Chang HL, Cheung TY, et al. Transmission of the severe acute respiratory syndrome on aircraft. N Engl J Med 2003; 349(25):2416-2422.
32. Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings. Lancet Infect Dis 2007; 7(4):257-265.
33. Tellier R. Aerosol transmission of influenza A virus: a review of new studies. J R Soc Interface 2009; 6(suppl 6):S783-S790.
34. Hemmes JH, Winkler KC, Kool SM. Virus survival as a seasonal factor in influenza and poliomyelitis. Nature 1960; 188:430-431.
35. Lowen A, Palese P. Transmission of influenza virus in temperate zones is predominantly by aerosol, in the tropics by contact: a hypothesis. PLoS Curr 2009; 1:RRN1002.
36. Lowen AC, Steel J, Mubareka S, Palese P. High temperature (30°C) blocks aerosol but not contact transmission of influenza virus. J Virol 2008; 82(11):5650-5652.
37. Lowen AC, Mubareka S, Steel J, Palese P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog 2007; 3(10):1470-1476. (Pubitemid 350085611)
38. Grayson ML, Melvani S, Druce J, et al. Efficacy of soap and water and alcohol-based hand rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis 2009; 48(3):285-291.
39. World Health Organization. Avian influenza guidelines, recommendations, descriptions. http://www.who.int/csr/disease/avian-influenza/guidelines/en. Accessed 15 April 2010.
40. Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA 2009; 302(17):1865-1871.
41. Institute of Medicine. Respiratory protection for healthcare workers in the workplace against novel H1N1 influenza A: a letter report. http://www.iom.edu/Reports/2009/RespProtH1N1.aspx. Accessed 15 April 2010.
42. Naidoo S, Jinabhai CC. Tuberculosis in health care workers in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2006; 10(6):676-682. (Pubitemid 43845030)
43. World Health Organization. 2009 update: tuberculosis facts. http://www.who.int/tb/publications/2009/tbfactsheet-tb-2009update-dec09.pdf. Accessed 19 February 2010.
44. World Health Organization. Countries that had reported at least one XDR-TB case by September 2009. http://www.who.int/tb/challenges/xdr/xdr-map- sep09.pdf. Accessed 19 February 2010.
45. Holtz TH, Sternberg M, Kammerer S, Laserson KL. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 114(9):650-659.
46. Ward HA, Marciniuk DD, Hoeppner VH, Jones W. Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants. Int J Tuberc Lung Dis 2005; 9(2):164-169. (Pubitemid 40278378)
47. Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis 2008; 47:450-457.
48. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008; 178:1075-1082.
49. Eker B, Ortmann J, Migliori GB, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14(11):1700-1706.
50. WHO-IUATLD. Anti-tuberculosis drug resistance in the world (report no. 4). WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008. http://whqlibdoc.who. int/hq/2008/who-htm-tb-2008.394-eng.pdf. Accessed 27 April 2010.
51. Calver AD, Falmer AA, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010; 16:264-271.
52. Gandi NR, Moll A, Sturm AW, et al. Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-1580.
53. World Health Organization (WHO). WHO policy on TB infection control in health-care facilities, congregate settings and households. WHO/HTMT/TB/2009. 419. Geneva, Switzerland: WHO, 2009. http://whqlibdoc.who.int/publications/2009/ 9789241598323-eng.pdf. Accessed 27 April 2010.
54. Bock NN, Jensen PA, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007; 196(suppl 1):S108-S113.
55. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-S247. (Pubitemid 30233180)
56. Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992; 41(RR-11):61-71.
57. Centers for Disease Control and Prevention. Regional Training and Medical Consultation Centers (RTMCCs). http://www.cdc.gov/TB/education/rtmc/default. htm. Accessed 19 February 2010.